Search

Relay Therapeutics Inc

Закрыт

СекторЗдравоохранение

19.12 2.96

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

18.17

Макс.

19.02

Ключевые показатели

By Trading Economics

Доход

-10M

-84M

Продажи

-2.7M

350K

Прибыль на акцию

-0.41

Рентабельность продаж

-23,916.286

Сотрудники

202

EBITDA

-10M

-83M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+49.27% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-65M

4B

Предыдущая цена открытия

16.16

Предыдущая цена закрытия

19.12

Новостные настроения

By Acuity

50%

50%

149 / 339 Рейтинг в Healthcare

Relay Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 сент. 2026 г., 20:08 UTC

News

Relay Therapeutics will participate in two investor conferences in September 2026. Shares are trading roughly flat since Tuesday's close, below the 20-day moving average.

31 авг. 2026 г., 20:07 UTC

Relay Therapeutics shares are lower today amid broader market pressures and concerns about inflation following the Jackson Hole Economic Symposium.

28 авг. 2026 г., 21:51 UTC

Relay Therapeutics Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions. No specific news was identified for this movement.

27 авг. 2026 г., 22:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, declining from earlier gains amid broader weakness and three consecutive sessions of losses.

26 авг. 2026 г., 20:08 UTC

Relay Therapeutics Inc is trading lower today amid broader market declines, influenced by inflation data that exceeded expectations and may impact Federal Reserve policy.

25 авг. 2026 г., 23:41 UTC

Relay Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

24 авг. 2026 г., 19:56 UTC

Social Media

Relay Therapeutics is testing a buy point at $20.79, reflecting ongoing interest. The stock remains higher since Friday's close despite an earlier pullback.

21 авг. 2026 г., 21:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, up significantly since Friday's close and above its 20-day moving average.

20 авг. 2026 г., 20:02 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower today, influenced by a decline in the broader Biotechnology sector and significant market volatility. Trading volume remains unusually high.

19 авг. 2026 г., 23:01 UTC

Relay Therapeutics Inc is trading higher in after-market hours, positioned near the upper end of its one-month range and above its 20-day moving average.

18 авг. 2026 г., 22:26 UTC

Relay Therapeutics Inc. shares traded lower after market hours, reflecting broader market pressure from rising bond yields and inflation concerns.

17 авг. 2026 г., 19:36 UTC

Social Media
News

Relay Therapeutics Inc is trading higher amid a Phase 3 trial for its breast cancer treatment and a $53 million investment from Baker Bros.

14 авг. 2026 г., 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 авг. 2026 г., 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 авг. 2026 г., 19:56 UTC

News
Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 авг. 2026 г., 20:06 UTC

News
Correlated Moves
Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 авг. 2026 г., 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 авг. 2026 г., 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 авг. 2026 г., 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 авг. 2026 г., 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 июл. 2026 г., 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 июл. 2026 г., 17:36 UTC

Correlated Moves
News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 июл. 2026 г., 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 июл. 2026 г., 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 июл. 2026 г., 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 июл. 2026 г., 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 июл. 2026 г., 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 июл. 2026 г., 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Сравнение c конкурентами

Изменение цены

Relay Therapeutics Inc Прогноз

Целевая цена

By TipRanks

49.27% рост

Прогноз на 12 месяцев

Средняя 27.63 USD  49.27%

Максимум 31 USD

Минимум 20 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Relay Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

9 ratings

9

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

149 / 339Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat